The study underscores the evolving treatment landscape in melanoma management, with a potential shift towards immune checkpoint inhibitors in the adjuvant setting, particularly for BRAF-mutated disease. However, limitations in meta-analysis methodologies and the need for long-term investigations into ...
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas Apr 3rd 2025 - May 9th 2025 online-activity View More Video Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How...
[38]. Yin T, Wang G, Wang L, et al. Breaking NGF-TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection. Nat Immunol. 2024;25(2):268-281. [39]. Wu N, Li J, Li L, et al. MerTK+ mac...
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...
Key data from Merck’s pipeline to be presented at ASCO 2024: First presentation of three-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940) in combination with KEYTRUDA as adjuvan...
Pyroptosis, a highly immunogenic type of cell death, initiates local inflammation and attracts inflammatory cells for infiltration. This offers an opportunity to alleviate the immune suppression within the tumor microenvironment (TME) and stimulate systemic immune responses during the treatment of solid ...
- Starting dose for most Cancers, including mRNA Vaccine Induced Turbo Cancers (lymphoma, breast cancer, colon cancer, lung cancer, melanoma, testicular/cervical/ovarian, kidney, etc)HIGH DOSE (2.0mg/kg)- Starting dose for aggressive Turbo Cancers, especially Leukemias, pancreatic, brain cancer- ...
et al. microRNA-10b is a prognostic biomarker for melanoma. Mod. Pathol. 29, 112–121 (2016). CAS PubMed Google Scholar Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341–347 (2010). A study that uses ...
Drug resistance represents a significant obstacle in cancer treatment, underscoring the need for the discovery of novel therapeutic targets. Ubiquitin-specific proteases (USPs), a subclass of deubiquitinating enzymes, play a pivotal role in protein deubi
(pcALCL) and mycosis fungoides who had been previously treated. Approval for the use of BV was based on the phase III ALCANZA trial, which showed a significant increase in an objective response lasting at least 4 months after BV treatment compared to the objective response to a physician’s ...